Noppadol Siritanaratkul

Author

Siriraj Hospital ORCID

Also Known As

N Siritanaratkul, N. Siritanaratkul, Noppadol Siritanaratkul, Siritanaratkul, N, Siritanaratkul, Noppadol

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Siriraj Hospital Mahidol University Chulalongkorn University National and Kapodistrian University of Athens Novartis (Switzerland)

About

Noppadol Siritanaratkul is an author at Siriraj Hospital specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	1.8K
2	Health Sciences	10	10	1.2K
3	Biochemistry	4	4	62
4	Public Health	3	3	146
5	Natural Sciences	2	2	28

Noppadol Siritanaratkul

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon, The Lancet Oncology Hematological MalignancyDouble-blind Phase 3MedicineDexamethasone Versus PlaceboHematology	2014	781
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma Tadeusz Robak, Huiqiang Huang, Jie Jin, New England Journal of Medicine	2015	375
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon, The Lancet Haematology Hematological MalignancyOncologyOverall SurvivalRelapsed Multiple MyelomaHematology	2016	143
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study Alì Taher, John B. Porter, Vip Viprakasit, Blood	2012	141
Improvement in oxidative stress and antioxidant parameters in β-thalassemia/Hb E patients treated with curcuminoids Ruchaneekorn W. Kalpravidh, Noppadol Siritanaratkul, Praphaipit Insain, Clinical Biochemistry Lipid PeroxidationPharmacologyβ-Thalassemia/hb E PatientsReactive Oxygen SpecieMedicine	2009	133
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study Tadeusz Robak, Jie Jin, Halyna Pylypenko, The Lancet Oncology Hematological MalignancyFrontline BortezomibLymphoid NeoplasiaTransplantationOncology	2018	132
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment Paul G. Richardson, Vânia Hungria, Sung‐Soo Yoon, Blood	2015	130
Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study Jae Hoon Lee, Jin Seok Kim, Chang Ki Min, American Journal of Hematology	2014	122
Clinical Manifestation of β-Thalassemia/Hemoglobin E Disease Suthat Fucharoen, Phairawh Ketvichit, Pensri Pootrakul, The American journal of pediatric hematology/oncology	2000	118
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial Andrew Davies, Francesco Merli, Biljana Mihaljević, The Lancet Haematology Lymphoid NeoplasiaMedicineFollicular LymphomaSubcutaneous RituximabIntravenous Rituximab	2017	112

Page 1